CN103298806B - 取代的哒嗪羧酰胺化合物 - Google Patents
取代的哒嗪羧酰胺化合物 Download PDFInfo
- Publication number
- CN103298806B CN103298806B CN201180057513.0A CN201180057513A CN103298806B CN 103298806 B CN103298806 B CN 103298806B CN 201180057513 A CN201180057513 A CN 201180057513A CN 103298806 B CN103298806 B CN 103298806B
- Authority
- CN
- China
- Prior art keywords
- disease
- alk
- compound
- compounds
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(c(c(Cl)ccc1F)c1Cl)Oc1c(*)nnc(C(Nc(cc2)ccc2C(N(CC2)CCC2N2CCCC2)=O)=O)c1 Chemical compound CC(c(c(Cl)ccc1F)c1Cl)Oc1c(*)nnc(C(Nc(cc2)ccc2C(N(CC2)CCC2N2CCCC2)=O)=O)c1 0.000 description 4
- QGOGPJSHFWRCKX-UHFFFAOYSA-O CC(c(c(Cl)c(cc1)F)c1Cl)OC(C=C(C(Nc(cc1)ccc1C(N1CC(C)(C)NCC1)=O)=O)[NH2+]1)=C1N(C(OC(C)(C)C)=O)C(OC(C)(C)C)=O Chemical compound CC(c(c(Cl)c(cc1)F)c1Cl)OC(C=C(C(Nc(cc1)ccc1C(N1CC(C)(C)NCC1)=O)=O)[NH2+]1)=C1N(C(OC(C)(C)C)=O)C(OC(C)(C)C)=O QGOGPJSHFWRCKX-UHFFFAOYSA-O 0.000 description 1
- SLENIDDYKZDPEO-UHFFFAOYSA-O CC(c(c(Cl)ccc1F)c1Cl)OC1=C(N)[NH2+]NC(C(Nc(cc2)ccc2C(N(CC2)CCC2N2CCCC2)=O)=O)=C1 Chemical compound CC(c(c(Cl)ccc1F)c1Cl)OC1=C(N)[NH2+]NC(C(Nc(cc2)ccc2C(N(CC2)CCC2N2CCCC2)=O)=O)=C1 SLENIDDYKZDPEO-UHFFFAOYSA-O 0.000 description 1
- UFMXINTVSWXXBW-UHFFFAOYSA-N CCN(CC1)CCN1C(c(cc1)ccc1NC(c1cc(OC(C)c(c(Cl)ccc2F)c2Cl)c(N)nn1)=O)=O Chemical compound CCN(CC1)CCN1C(c(cc1)ccc1NC(c1cc(OC(C)c(c(Cl)ccc2F)c2Cl)c(N)nn1)=O)=O UFMXINTVSWXXBW-UHFFFAOYSA-N 0.000 description 1
- ZTYNIDYMOZVEKC-OAHLLOKOSA-N C[C@H](c(c(Cl)ccc1F)c1Cl)OC1=C(N)NN(C)C(C(Nc(cc2)ccc2C(N2CC(C)(C)NCC2)=O)=O)=C1 Chemical compound C[C@H](c(c(Cl)ccc1F)c1Cl)OC1=C(N)NN(C)C(C(Nc(cc2)ccc2C(N2CC(C)(C)NCC2)=O)=O)=C1 ZTYNIDYMOZVEKC-OAHLLOKOSA-N 0.000 description 1
- UVWOOYAWHQBILO-NNJIEVJOSA-N C[C@H](c(c(Cl)ccc1F)c1Cl)Oc1c(N)nnc(C(Nc(cc2)ccc2C(N2CC(CCC3)N3CC2)=O)=O)c1 Chemical compound C[C@H](c(c(Cl)ccc1F)c1Cl)Oc1c(N)nnc(C(Nc(cc2)ccc2C(N2CC(CCC3)N3CC2)=O)=O)c1 UVWOOYAWHQBILO-NNJIEVJOSA-N 0.000 description 1
- NOGPNWIYEOWJDC-UHFFFAOYSA-N Nc(cc1)ccc1C(N(CC1)CCC1N1CCCC1)=O Chemical compound Nc(cc1)ccc1C(N(CC1)CCC1N1CCCC1)=O NOGPNWIYEOWJDC-UHFFFAOYSA-N 0.000 description 1
- ZYZRABIDXQOCME-UHFFFAOYSA-N Nc(cc1)ccc1C(N1CC(CCC2)N2CC1)=O Chemical compound Nc(cc1)ccc1C(N1CC(CCC2)N2CC1)=O ZYZRABIDXQOCME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39142310P | 2010-10-08 | 2010-10-08 | |
| US61/391,423 | 2010-10-08 | ||
| PCT/US2011/055428 WO2012048259A2 (en) | 2010-10-08 | 2011-10-07 | Substituted pyridazine carboxamide compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103298806A CN103298806A (zh) | 2013-09-11 |
| CN103298806B true CN103298806B (zh) | 2015-03-18 |
Family
ID=45928473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180057513.0A Active CN103298806B (zh) | 2010-10-08 | 2011-10-07 | 取代的哒嗪羧酰胺化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9126947B2 (https=) |
| EP (1) | EP2625176B1 (https=) |
| JP (2) | JP6023062B2 (https=) |
| KR (1) | KR101886812B1 (https=) |
| CN (1) | CN103298806B (https=) |
| AU (1) | AU2011311814B2 (https=) |
| BR (1) | BR112013008523B1 (https=) |
| CA (1) | CA2813607C (https=) |
| EA (1) | EA024809B1 (https=) |
| ES (1) | ES2610226T3 (https=) |
| PL (1) | PL2625176T3 (https=) |
| WO (1) | WO2012048259A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017206924A1 (zh) | 2016-06-01 | 2017-12-07 | 贝达药业股份有限公司 | 抑制蛋白激酶活性化合物的晶型及其应用 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2550264B1 (en) * | 2010-03-23 | 2016-06-08 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| EA024809B1 (ru) * | 2010-10-08 | 2016-10-31 | Икскавери Холдинг Кампани, Ллс | Замещенные соединения пиридазинкарбоксамида |
| JP6013029B2 (ja) * | 2012-05-25 | 2016-10-25 | 千葉県 | 抗癌剤 |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| CN105085550B (zh) * | 2014-05-21 | 2017-05-24 | 海门慧聚药业有限公司 | 一类alk激酶抑制剂及其制备方法 |
| RU2015110071A (ru) * | 2015-03-23 | 2016-10-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО "ФармТех" | Применение новых химических соединений (варианты) в качестве ингибиторов nuak1 киназы для лечения онкологических заболеваний |
| RU2631430C1 (ru) * | 2016-10-26 | 2017-09-22 | Общество С Ограниченной Ответственностью "Отечественные Фармацевтические Технологии" | НОВЫЙ СПОСОБ СИНТЕЗА ПРОИЗВОДНЫХ ТЕТРАГИДРОПИРАЗИНО[2,3-c]ПИРИДАЗИНА |
| CN110357889B (zh) * | 2018-04-09 | 2022-03-15 | 上海科技大学 | 蛋白降解靶向化合物、其抗肿瘤应用、其中间体及中间体应用 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| EP4188922A1 (en) | 2020-08-03 | 2023-06-07 | Teva Pharmaceuticals International GmbH | Solid state forms of ensartinib and ensartinib salts |
| EP4385510A4 (en) * | 2021-08-10 | 2025-08-20 | Betta Pharmaceuticals Co Ltd | USE OF ENSARTINIB OR A CORRESPONDING SALT IN THE TREATMENT OF A DISEASE CARRYING A MET EXON 14 SKIPPING MUTATION |
| CN116082110B (zh) * | 2023-01-09 | 2024-04-12 | 北京肿瘤医院(北京大学肿瘤医院) | 一种11c标记靶向间变性淋巴瘤激酶alk突变分子探针及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009154769A1 (en) * | 2008-06-19 | 2009-12-23 | Xcovery, Inc. | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| DE3583799D1 (de) | 1985-01-11 | 1991-09-19 | Abbott Lab Ltd | Feste zubereitung mit langsamer freisetzung. |
| JP2773959B2 (ja) | 1990-07-10 | 1998-07-09 | 信越化学工業株式会社 | 大腸内放出性固形製剤 |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| DE69924735T2 (de) | 1998-07-28 | 2006-01-19 | Tanabe Seiyaku Co., Ltd. | Zur wirkstoffabgabe an zielorten im darm fähige zubereitung |
| US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
| US6800663B2 (en) | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| CA2517256C (en) | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| BRPI0514687A (pt) * | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
| ME01309B (me) | 2004-08-26 | 2013-12-20 | Pfizer | Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza |
| WO2008088881A1 (en) | 2007-01-19 | 2008-07-24 | Xcovery, Inc. | Kinase inhibitor compounds |
| EA024809B1 (ru) * | 2010-10-08 | 2016-10-31 | Икскавери Холдинг Кампани, Ллс | Замещенные соединения пиридазинкарбоксамида |
| WO2012048258A2 (en) * | 2010-10-08 | 2012-04-12 | Xcovery Holding Company, Llc | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
-
2011
- 2011-10-07 EA EA201390520A patent/EA024809B1/ru unknown
- 2011-10-07 PL PL11831702T patent/PL2625176T3/pl unknown
- 2011-10-07 KR KR1020137011872A patent/KR101886812B1/ko active Active
- 2011-10-07 CN CN201180057513.0A patent/CN103298806B/zh active Active
- 2011-10-07 AU AU2011311814A patent/AU2011311814B2/en active Active
- 2011-10-07 EP EP11831702.3A patent/EP2625176B1/en active Active
- 2011-10-07 JP JP2013532985A patent/JP6023062B2/ja active Active
- 2011-10-07 US US13/877,783 patent/US9126947B2/en active Active
- 2011-10-07 WO PCT/US2011/055428 patent/WO2012048259A2/en not_active Ceased
- 2011-10-07 BR BR112013008523-1A patent/BR112013008523B1/pt active IP Right Grant
- 2011-10-07 CA CA2813607A patent/CA2813607C/en active Active
- 2011-10-07 ES ES11831702.3T patent/ES2610226T3/es active Active
-
2015
- 2015-09-04 US US14/846,490 patent/US20160068493A1/en not_active Abandoned
-
2016
- 2016-06-23 JP JP2016124463A patent/JP6235078B2/ja active Active
-
2017
- 2017-05-03 US US15/585,961 patent/US20180016240A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009154769A1 (en) * | 2008-06-19 | 2009-12-23 | Xcovery, Inc. | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017206924A1 (zh) | 2016-06-01 | 2017-12-07 | 贝达药业股份有限公司 | 抑制蛋白激酶活性化合物的晶型及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US9126947B2 (en) | 2015-09-08 |
| EP2625176A2 (en) | 2013-08-14 |
| KR101886812B1 (ko) | 2018-08-08 |
| BR112013008523A2 (pt) | 2016-07-12 |
| JP2016216475A (ja) | 2016-12-22 |
| KR20130141514A (ko) | 2013-12-26 |
| PL2625176T3 (pl) | 2017-08-31 |
| EP2625176B1 (en) | 2016-08-17 |
| JP2013539765A (ja) | 2013-10-28 |
| AU2011311814B2 (en) | 2016-12-22 |
| BR112013008523B1 (pt) | 2021-12-07 |
| CA2813607A1 (en) | 2012-04-12 |
| US20130190298A1 (en) | 2013-07-25 |
| US20160068493A1 (en) | 2016-03-10 |
| JP6023062B2 (ja) | 2016-11-09 |
| WO2012048259A3 (en) | 2012-06-28 |
| US20180016240A1 (en) | 2018-01-18 |
| AU2011311814A1 (en) | 2013-05-02 |
| EA024809B1 (ru) | 2016-10-31 |
| WO2012048259A2 (en) | 2012-04-12 |
| ES2610226T3 (es) | 2017-04-26 |
| CA2813607C (en) | 2021-08-31 |
| CN103298806A (zh) | 2013-09-11 |
| EA201390520A1 (ru) | 2013-09-30 |
| JP6235078B2 (ja) | 2017-11-22 |
| EP2625176A4 (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103298806B (zh) | 取代的哒嗪羧酰胺化合物 | |
| US9000023B2 (en) | Disubstituted phthalazine hedgehog pathway antagonists | |
| JP5670325B2 (ja) | キナーゼ阻害化合物としての置換されたピリダジンカルボキサミド化合物 | |
| CN108137576A (zh) | 用于治疗癌症的、为共济失调毛细血管扩张症突变型（atm）激酶的选择性调节剂的8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4,5-c]喹啉-2-酮衍生物 | |
| WO2017092413A1 (zh) | 一种二氨基嘧啶化合物及包含该化合物的组合物 | |
| JP6832923B2 (ja) | ブロモドメイン阻害薬としての２−オキソ−１，２−ジヒドロピリジン−３，５−ジカルボキサミド化合物 | |
| US20240408064A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
| CN106687446A (zh) | 作为t790m/wt‑egfr的选择性和不可逆的激酶抑制剂的5‑氨基‑4‑氨甲酰基‑吡唑化合物及其用途 | |
| AU2016262642A1 (en) | Substituted pyridazine carboxamide compounds as kinase inhibitor compounds | |
| TW201922709A (zh) | 表皮生長因子受體抑制劑 | |
| JP2026509598A (ja) | アゼチジンｐａｒｐ１阻害剤の結晶形態 | |
| KR20220122597A (ko) | 약학적 화합물 | |
| HK1188216B (en) | Substitututed 6-amino-pyridazin-3-yl-carboxamide compounds as protein kinase modulators | |
| HK40004229A (en) | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: BETA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: TYROGENEX INC. Effective date: 20150109 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 311199 HANGZHOU, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150109 Address after: 311199 No. 589 Hongfeng Road, Yuhang economic and Technological Development Zone, Zhejiang, Hangzhou Applicant after: Beta Pharmaceutical Co., Ltd. Address before: American Florida Applicant before: Xcovery Holding Company LLC |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |